Catheter Precision today announced that more than 800 procedures have been performed using its VIVO System in the U.S. and Europe.
The VIVO (View Into Ventricular Onset) System allows physicians to noninvasively identify an area of ventricular arrhythmia onset. It uses noninvasive 3D imaging that identifies the origin of arrhythmias pre-procedure.
“We are always looking to the next milestone in clinical usage of our VIVO System and reaching 800 procedures by the end of 2022 was a goal we set earlier this year,” CEO David Jenkins said in a news release. “We are gratified by physician adoption so far through our strategic limited launch and look forward to expanding usage in 2023 by growing our sales and clinical support teams to access additional hospitals in new and existing territories. By expanding our footprint, we are bringing a valuable tool to electrophysiologists to help them gain a better understanding of patient anatomy and potentially improve outcomes while providing beneficial healthcare to more patients.”
VIVO has received FDA marketing clearance in the U.S. and has received CE mark approval in Europe. The company plans to pursue a second generation of Amigo, a robotic arm that can be used to remotely control catheters outside of the procedure room.
Catheter Precision announced in September a definitive merger agreement with Ra Medical Systems that would focus on cardiac electrophysiology. Under the terms of the agreement, Catheter Precision will become a wholly-owned subsidiary of Ra Medical.
